## **CHECKPOINT**

# **ADL Bionatur**

### A strong operational start of the year

Analyst: Guillermo Serrano - gfs@checkpoint-partners.com

- ADL Bionatur has released a strong set of 1Q19 sales and a positive Ebitda number, as well as a sales guidance for 2019.
- Reported revenues of €10 million in 1Q19 was more than double compared to the €4.2 million of 1Q18. The reported €114k of Ebitda represented a marked improvement form the €2.8 million Ebitda loss in 1Q18.
- The main growth driver remains the CMO division with €8 million in turnover, almost triple the number compared to last year. ADL Bionatur continues to deliver on the contracts signed with its multinational clients to produce fermentation based ingredients.
- The main competitive advantages continue to be based on its European location, an opportunistically low cost of capacity installed coupled with a proven scientific skillset in scaling up biological processes.
- · The lower margin and smaller APIs division did not fare as well during the quarter with a reported 14% decline in sales to €900k. Alternatively, the remaining divisions (grouped under Other) rose 205% suggesting that activity is very strong there.
- · The company has reported sales guidance of between €50-€55 million, but we maintain our estimates unchanged for now.
- The CMO division has plenty of room to continue to grow over the next several years and, on an asset value basis, is currently trading at an estimated 50% discount over its replacement value. We maintain. Our 12-month target price of €3.20.

Target Price: €3.20

7am, 9h May 2019


Equities

Spain Biotechnology

Price (4pm 07/05/19): €2.35 RIC: ADL.MC Target Price (12 months): €3.20

52 week range (€):	1.61 - 2.60
Mkt Cap (€ millions):	92,6
No. Shares (millions):	39.4
Avg Daily vol (€ LTM):	19,501

#### Share Price Chart (LTM)



(€ millions)	2017	2018e	2019f	2020f
Sales	14,6	25,3	63,4	83,7
Ebitda	-8,1	-8,7	8,5	19,5
Net Income	-12,8	-16,7	2,2	12,8
EPS (cents)	-0,33	-0,42	0,06	0,33
Net Debt	28,9	41,7	51,3	52,3
P/E (x)	n.m.	n.m.	42,3	7,2
EV/EBITDA (x)	n.m.	n.m.	16,9	7,4
EV/Sales (x)	8,3	5,3	2,3	1,7

BUY

This report has been prepared by Checkpoint Partners (España) SLU



#### Disclaimer:

Checkpoint Partners (España) SLU [Checkpoint] is a Madrid based specialist corporate finance company specialized on providing financial advice to emerging technology companies. More information can be obtained in our website www.checkpoint-partners.com or by writing to us at gfs@checkpoint-partners.com

Checkpoint has obtained this information from various sources including the company mentioned in this report. It has been verified to the best of Checkpoint's ability, however it has not been independently verified and no representation is made, nor warranty given as to the accuracy, completeness, or the reasonableness of any statements of opinion, belief or the achievability of any forecasts or projections contained within this report.

Checkpoint does and seeks to do business with companies covered in its research reports. As a result, investors may take the view this could affect the objectivity of the report and therefore should consider this report as only a single factor in making their investment decision.

Furthermore, this report has been written in accordance to the Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest.

Checkpoint does not provide advice with regards legal and tax matters. This should be referred to the appropriate professionals. Past performance is not a guarantee for future returns. Currencies denominated investments are subject to fluctuations in exchange rates that could have an effect on the Investor's return. Prices of investments may fluctuate and therefore you may not get back your original investment. The distribution, reproduction or other use of all or any part of this report is prohibited. Neither this report nor any of the accompanying documents or information may be reproduced in whole or in part, nor may they be used for any purpose other than that for which they have been submitted, without the prior written consent of Checkpoint. This report is only available within the European Economic Area.



## The CMO division continues to drive the growth at ADL Bionatur in 1Q19

The CMO division remains strong and generated sales of slightly over 50% compared to the whole of 2018 put together. Although largely expected, it provides evidence that ADL is able to deliver on its contractual agreements with customers.

ADL Bionatur is a beneficiary of a relative shortage of high quality fermentation capacity in Europe in an environment where genetic engineering continues to stimulate innovation in the industrial biotechnology sector. We continue to expect the CMO division to grow over the following quarters.

Business Areas	Q1 2019	Q1 2018	(%)
€´000			
Total Income	9.968	4.259	134%
СМО	8.015	2.859	180%
APIs	903	1.055	-14%
Others	1.050	344	205%
CMO (%total)	80%	67%	
APIs (%total)	<u>9%</u>	25%	
Others (%total)	11%	8%	
EBITDA	114	(2.850)	

The API division is mostly devoted to the antibiotics value chain and specifically in the chemical semi-synthesis part of the process. The growth in this division is mainly dependent on the filing and approval of API dossiers that were originally acquired from the former Antibioticos. Its a lower margin business compared to the CMO division, so the relative impact on this results is fairly subdued.

Under others, the robust 205% increase in numbers include the remaining 4 business areas of Bionaturis, ZIP, Biobide and the hosting services to Wacker Chemie.

The positive Ebitda number is encouraging and a demonstration that there is operational leverage as sales grow and capacity utilization at the Leon plant increases. We expect the trend to continue with rising sales.



Profit and loss account	2017	2018e	2019f	2020f
СМО	n.a.	15,7	49,8	58,0
Propietary Products	n.a.	5,6	9,5	21,3
R&D Services	n.a.	1,7	2,1	2,3
Other	n.a.	2,3	2,0	2,1
Revenues	15,2	25,3	63,4	83,7
Cost of good sold	5,2	10,6	24,8	29,9
Gross Profit	10,0	14,6	38,6	53,8
Gross Margin	66 %	58 %	61 %	64 %
Capitalized R+D	2,3	1,9	3,0	3,1
Personnel costs	11,3	13,4	16,0	16,3
Other SG&A	10,9	11,9	17,1	21,1
Depreciation	2,2	2,7	3,6	4,3
Operating profit	-12,1	-11,4	4,9	15,2
Operating Margin	-79 %	-45 %	8 %	18 %
Ebitda	-9,9	-8,7	8,5	19,5
Margin	-65 %	-34 %	13 %	23 %
Ebitda (ex-cap) *	-12,1	-10,6	5,5	16,4
Margin	-80 %	-42 %	9 %	20 %
Extraordinaries	0,0	-3,5	-0,3	0,0
Financial income	0,1	0,0	0,1	0,0
Financial Expenses	1,2	1,9	2,5	2,4
Income before tax	-13,1	-16,8	2,2	12,8
Income tax	-0,4	-0,1	0,0	0,0
Net profit	-12,8	-16,7	2,2	12,8

\* excludes capitalized R&D

Source: Checkpoint, ADL Bionatur

#### **CHECKPOINT**



Beyond the short term, we believe the lower cost associated to future capacity expansions places ADL Bionatur in an optimal position to continue to create value for shareholders.

The equity story continues to be based on the operational leverage created by rising levels of capacity utilization in its Leon based plant. As sales grow, the fixed costs associated with running the operation drop and with it, we expect future quarters of rising Ebitda margins.

The main risks associated with future profitability are related to "bad execution" of fermentation batches, a risk we believed to be contained by the long working tradition at the company in dealing with scale-up issues at the plant. In addition, each new contract is de-risked as ADL Bionatur works closely with the client to resolve any scale up issues associated with the fermentation process of the new organism.

Beneath the industrial story, we remain positive on the more R&D based divisions that over time have the capacity to generate large returns relative to the capital invested. From the Biotaturis recombinant vaccines, to the zebra based animal models to the reagent business, they provide a platform for R&D driven value generation.

	2017	2018e	2019f	2020f
Net Debt	n.m.	41,7	51,3	52,3
Net debt/ Equity	n.m.	197 %	229 %	153 %
Cash Ebitda/Interest costs	n.m.	n.m.	2,3	6,9
Net debt / Cash Ebitda	n.m.	n.m.	9,3	3,2
Working Capital (€ millions)	n.m.	5,0	5,7	8,5
Debtors (days)	n.m.	123	60	60
Creditors (days)	n.m.	154	80	70
Stock Turnover (days)	n.m.	225	65	56

Source: Checkpoint Partners

#### **CHECKPOINT**



€ millions	2017	2018e	2019f	2020f
Fixed Assets	14,5	58,6	68,8	78,7
Intanglible assets	7,8	14,1	16,4	18,7
Tangible assets	3,1	37,4	46,7	55,3
Real Estate investments	0,0	1,1	1,1	1,1
Long term financial investments	0,1	1,3	1,3	1,3
Deferred taxation	3,5	4,8	3,4	2,4
Current Assets	3,1	20,6	18,0	22,5
Inventory	0,0	6,6	4,4	4,6
Commercial and other debtors	1,6	8,9	10,4	13,8
Short term financial investments	0,9	1,2	1,2	1,2
Cash	0,5	4,0	2,0	3,0
Assets	17,6	79,2	86,8	101,1
Shareholders funds	8,0	21,2	22,4	34,2
Long term liabilities	7,6	38,2	44,1	35,4
Long term financial debt	7,2	30,7	38,1	34,8
Long term debt (w/ related parties)	0,0	7,0	5,5	0,0
Deferred taxation	0,4	0,5	0,5	0,5
Current liabilities	2,0	19,9	20,3	31,5
Short term financial debt	0,8	8,8	10,6	21,2
Commercial and creditors	1,2	10,5	9,2	9,8
Liabilities Source: Checkpoint Partners	17,6	79,2	86,8	101,1

Source: Checkpoint Partners



Division	Unit	DCF (€)	Year	Target EV / Sales	Target EV / Ebitda	Target P/E	5 yr Sales Growth	Long term Sales Growth
СМО	N4	110,9	2019	2,3	17,0	23,0	36 %	3 %
			2020	2,0	11,1	12,9		
	N3	7,6	2019	6,1	57,0	98,2	n.m.	2 %
			2020	3,0	8,0	7,3		
Propietary Products		26,1	2019	2,7	n.m	n.m	36 %	4 %
			2020	1,2	7,4	8,0		
<b>R&amp;D Services</b>		9,4	2019	4,5	11,2	11,2	20 %	4 %
			2020	4,1	9,8	7,4		
Other		13,6	2019	6,8	17,4	15,4	16 %	4 %
			2020	6,6	18,0	16,3		
Sum of Parts		167,6	2019	2,6	31,9	n.m.	36 %	3 %
			2020	2,0	10,4	9,8		

#### Sum of the parts valuation

Source: Checkpoint Partners



#### **Checkpoint Recommendation System**

The Checkpoint Recommendation System is based on absolute returns, measured by the upside potential (including dividends and capital reimbursement) over a 12month time horizon. Checkpoint recommendations (or ratings) for each stock comprises 3 categories: Buy (B), Neutral (N) and Sell (S).

- **Buy:** the stock is expected to generate total return of over 20% during the next 12 months time horizon
- **Neutral:** the stock is expected to generate total return of -20% to +20% during the next 12 months time
- Sell: the stock is expected to generate total return under -20% during the next 12 months time horizon.

Our rating system applies to companies with market capitalizations of near or below €50 million that in most cases refer to stocks that are illiquid and more volatile than its larger sized peers.

#### History of recommendations

Date	Recommen.	Price (€)	Target P.(€)	Period	Analyst
11.2.2019	BUY	2.12	3.20	12 months	Guillermo Serrano
08.4.2019	BUY	2.16	3.20	12 months	Guillermo Serrano

Checkpoint does and seeks to do business with companies covered in its research reports. As a result, investors may take the view this could affect the objectivity of the report and therefore should consider this report as only a single factor in making their investment decision.

#### Frequency of analyst reports

At present Checkpoint has committed to a quarterly update of ADL Bionatur financial and operational performance.

#### Investment horizon

Our reports focus mainly on small capitalization and illiquid stocks where standard Venture Capital investment criteria should apply. An investment into a sub or near €50 million market capitalization stock, specially if it is illiquid, should be done on a 3-5 year time horizon in order to realize the full potential of the investment opportunity.

#### Date of publication

7am, 9th May 2019



# CHECKPOINT